A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis
- PMID: 20532833
- DOI: 10.1007/s11695-010-0204-1
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis
Abstract
Background: Patients with biopsy-proven NASH and especially those with fibrosis are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH-related fibrosis.
Aim: This study examines the performance of a new biomarker panel for NASH and NASH-related fibrosis with a combination of clinical and laboratory variables.
Methods: Enrolled patients had biopsy-proven NAFLD. Clinical data, laboratory data, and serum samples were collected at the time of biopsy. Fasting serum was assayed for adiponectin, resistin, glucose, M30, M65, Tissue inhibitor of metalloproteinases-1 (Timp-1), ProCollagen 3 N-terminal peptide (PIIINP), and hyaluronic acid (HA). Regression models predictive of NASH, NASH-related fibrosis, and NASH-related advanced fibrosis were designed and cross-validated.
Results: Of the 79 enrolled NAFLD patients, 40 had biopsy-proven NASH and 39 had non-NASH NAFLD. Clinical and laboratory data were from this cohort were used to develop a NAFLD Diagnostic Panel that includes three models (models for NASH, NASH-related fibrosis, and NASH-related advanced fibrosis). The model for predicting NASH includes diabetes, gender, BMI, triglycerides, M30 (apoptosis), and M65-M30 (necrosis) [AUC: 0.81, 95% CI, 0.70-0.89, 300 p value <9E 301 (-06)]. The NASH-related fibrosis prediction model includes the same predictors [AUC: 0.80, 95% CI 0.68-0.88, 307 p value <0.00014]. Finally, the NASH-related advanced fibrosis model includes type 2 diabetes, serum triglycerides, Timp-1, and AST [AUC: 0.81, 95% CI, 0.70-0.89; p value, 0.000062].
Conclusions: This NAFLD Diagnostic Panel based on a clinical and laboratory data has good performance characteristics and is easy to use. This biomarker panel could become useful in the management of patients with NAFLD.
Comment in
-
Multimarker strategies for detecting NASH and NASH-related fibrosis: promises and caveats.Obes Surg. 2011 Aug;21(8):1316-7; author reply 1318. doi: 10.1007/s11695-011-0464-4. Obes Surg. 2011. PMID: 21667321 No abstract available.
Similar articles
-
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030. Hepatology. 2013. PMID: 22930399 Clinical Trial.
-
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol. 2009 Apr;24(4):564-8. doi: 10.1111/j.1440-1746.2008.05731.x. J Gastroenterol Hepatol. 2009. PMID: 19378390
-
Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.Eur J Gastroenterol Hepatol. 2018 Jun;30(6):637-644. doi: 10.1097/MEG.0000000000001079. Eur J Gastroenterol Hepatol. 2018. PMID: 29384795
-
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.Am J Gastroenterol. 2021 Feb 1;116(2):254-262. doi: 10.14309/ajg.0000000000001054. Am J Gastroenterol. 2021. PMID: 33284184 Review.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.J Hepatol. 2018 Feb;68(2):305-315. doi: 10.1016/j.jhep.2017.11.013. Epub 2017 Dec 2. J Hepatol. 2018. PMID: 29154965 Review.
Cited by
-
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115. Metabolites. 2023. PMID: 37999211 Free PMC article. Review.
-
The Effect of Laparoscopic Sleeve Gastrectomy and Gastric Bypass Surgery on Non-Alcoholic Steatohepatitis in Iranian Patients with Obesity.Middle East J Dig Dis. 2021 Jul;13(3):200-207. doi: 10.34172/mejdd.2021.226. Epub 2021 May 11. Middle East J Dig Dis. 2021. PMID: 36606220 Free PMC article.
-
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?Biology (Basel). 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237. Biology (Basel). 2022. PMID: 36009862 Free PMC article. Review.
-
Non-invasive tests of non-alcoholic fatty liver disease.Chin Med J (Engl). 2022 Jan 27;135(5):532-546. doi: 10.1097/CM9.0000000000002027. Chin Med J (Engl). 2022. PMID: 35089884 Free PMC article. Review.
-
acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.EClinicalMedicine. 2021 Oct 1;41:101145. doi: 10.1016/j.eclinm.2021.101145. eCollection 2021 Nov. EClinicalMedicine. 2021. PMID: 34646997 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous